ORIGINAL ARTICLE

Prevalence and Antimicrobial Resistance of *Ureaplasma urealyticum* and *Mycoplasma hominis* in Patients with Genital Tract Infection in Jiangsu, China

Ruixiang Luo ^{#, 1}, Kang Xun ^{#, 2}, Lingli Zuo ^{1, 2}, Feifei Sha ², Yun Chen ¹, Nong Yu ¹, Donghua Jin ², Yuxian Xie ², Meiling He ^{*, 1, 2}, Fang Liu ^{*, 1}

[#]Ruixiang Luo and Kang Xun contributed equally to this work

¹ Department of Medical Microbiology, The People's Hospital of Suzhou New District, Suzhou, Jiangsu, P. R. China

² Department of Nephrology, The People's Hospital of Suzhou New District, Suzhou, Jiangsu, P. R. China

SUMMARY

Background: The aim of this study was to investigate the infection and antimicrobial resistance of *Ureaplasma* urealyticum (*U. urealyticum*) and *Mycoplasma hominis* (*M. hominis*) in patients with genital tract diseases in Jiangsu, China.

Methods: A total of 3,321 patients suspected with genital tract infectious diseases were enrolled in this study from September 2017 to September 2020. The *Mycoplasma* detection and antimicrobial susceptibility were tested using the commercially available *Mycoplasma* kit.

Results: Among the 3,321 specimens tested, 1,503 (45.3%) were positive for Mycoplasmas, and the proportion of mono-infection of *U. urealyticum* is highest (79.5%). The overall infection rate has been increasing in the past 3 years. The positive rate in females (68.7%) was higher than in males (25.0%), and the main infection age group was 20 - 39 (81.2%). Besides, *U. urealyticum* and *M. hominis* displayed relative lower resistance rates to gatifloxacin, josamycin, minocycline, and doxycycline (6.0%, 6.5%, 3.1%, and 3.2%, respectively). However, the antimicrobial resistance rates to azithromycin, clindamycin, roxithromycin, sparfloxacin, and ofloxacin were relatively high (45.4%, 42.1%, 34.9, 36.0, and 65.5%, respectively). Antimicrobial resistance of *U. urealyticum* and *M. hominis* to these 14 drugs have been changing in the past 3 years.

Conclusions: In total, these preliminary data showed the prevalence and antimicrobial resistance status of *U. urealyticum* and *M. hominis* in patients suspected with genital tract infectious diseases, which has use for reference on both prevention and treatment of diseases caused by them.

(Clin. Lab. 2022;68:xx-xx. DOI: 10.7754/Clin.Lab.2021.210706)

Correspondence:

Meiling He and Fang Liu
Department of Medical Microbiology
The People's Hospital of
Suzhou New District No. 95
Hua Shan Road
Suzhou
Jiangsu 215000
P. R. China

Phone: + 86 512-69585033 Fax: + 86 512-69585033

Email: Meiling He: meilinghe8@163.com Fang Liu: 296659564@qq.com

Manuscript accepted September 21, 2021

Clin. Lab. 6/2022

Supplementary Tables and Figures

Table S1. Trend of the positive rates of Mycoplasmas of males and females respectively in endocervical or urethral specimens each year.

Year	2017 - 2018	2018 - 2019	2019 - 2020
Positive cases (males)	76	185	185
Sample size (males)	418	704	661
Positive rates (males) (%)	<u>18.2</u>	<u>26.3</u>	<u>28.0</u>
Positive cases (females)	231	360	466
Sample size (females)	330	517	691
Positive rates (females) (%)	<u>70</u>	<u>69.6</u>	<u>67.4</u>

2 Clin. Lab. 6/2022